Ripple Therapeutics

Based in Canada, Ripple Therapeutics is a startup. Its most recent tracked round is Series A. Brouky classifies it under Healthcare & Life Sciences.

Ripple Therapeutics is a clinical-stage company developing polymer-free, prodrug-based sustained-release implants (the Epidel® platform) to provide long-duration, controllable delivery of ophthalmic therapeutics for retinal diseases and glaucoma. The company engineers prodrugs that undergo surface erosion to enable constant drug release and is pursuing partnerships and clinical programs for indications such as DME, RVO, dry AMD/GA and glaucoma.